Targeting Epigenetics in Drug Discovery
Copyright policy )Targeting Epigenetics in Drug Discovery
This Special Issue of ChemMedChem on Epigenetics and Drug Discovery brings together a diverse group of papers on a range of topics from bromodomain inhibitors and long noncoding RNAs to classic agents targeting histone deacetylases (HDACs) and less typical HDAC inhibitors, such as the chimeric compounds designed by Greg Thatcher et al. and featured on the Front Cover of the issue that both target HDACs and act as selective estrogen receptor modulators (SERMs).
- University of Rome Tor Vergata Italy
- Roma Tre University Italy
- Sapienza University of Rome Italy
humans; drug discovery; epigenesis, genetic; pharmacology, toxicology and pharmaceutics (all); organic chemistry; molecular medicine, Drug Discovery, Humans, Epigenesis, Genetic
humans; drug discovery; epigenesis, genetic; pharmacology, toxicology and pharmaceutics (all); organic chemistry; molecular medicine, Drug Discovery, Humans, Epigenesis, Genetic
citations The total number of citations received by all articles of the researcher of interest.12 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
Citations provided by BIP!Popularity provided by BIP!